Prostate Cancer

News

Hypofractionated Radiotherapy Noninferior to Conventional Radiotherapy

02/28/2019

Hypofractionated radiotherapy is noninferior to conventional radiotherapy in men with low-risk prostate cancer, yielding no differences in QoL.

Hypofractionated radiotherapy is...

02/28/2019

Oncology

Podcasts

Enzalutamide–ADT Combo significantly Improves PFS in Metastatic Hormone-Sensitive Prostate Cancer

02/26/2019

Andrew J. Armstrong, MD, discusses the findings of his team’s recent study on the use of enzalutamide plus ADT versus ADT alone in patients with metastatic hormone sensitive prostate cancer.

Andrew J. Armstrong, MD,...

02/26/2019

Oncology

Interview

MDT Viable for Patients With Metastatic HSPC Wanting to Defer Systemic Therapy

02/21/2019

Neil R. Parikh, MD, discusses the cost-effectiveness of using MDT in the treatment of patients with oligometastatic HSPC.

Neil R. Parikh, MD, discusses...

02/21/2019

Oncology

Podcasts

Survival Benefits of PARP Inhibitors in Metastatic CRPC Favor BRCA1/2 Over ATM Mutations

02/21/2019

Catherine Handy Marshall, MD, MPH, talks about the different responses to PARP inhibitor therapy seen in patients with metastatic CRPC and BRCA1/2 versus ATM mutations.

Catherine Handy Marshall, MD,...

02/21/2019

Oncology

Pembrolizumab–Olaparib Combo Effective in Patients With CRPC Previously Treated With Docetaxel

02/19/2019

Results from a recent clinical trial demonstrate the efficacy of combining pembrolizumab and olaparib therapy in patients with metastatic CRPC.

Results from a recent clinical...

02/19/2019

Oncology

Podcasts

Apalutamide Significantly Delays Metastasis in SPARTAN Trial of Nonmetastatic CRPC

02/14/2019

Julie N. Graff, MD, discusses the promising results of the SPARTAN clinical trial of apalutamide in patients with nonmetastatic CRPC.

Julie N. Graff, MD, discusses...

02/14/2019

Oncology

Biomarkers Identify and Distinguish Low VS Intermediate and High Prostate Cancer Risk

01/04/2019

Large chromosomal rearrangements yield biomarkers that can identify and distinguish individuals with low versus intermediate and high risk for prostate cancer, a recent study shows.

Large chromosomal rearrangements...

01/04/2019

Oncology

Enzyme-Based Biomarker Promising as Diagnostic Tool for Prostate Cancer

09/12/2018

Plasma GOAT enzyme levels show promise as a potential noninvasive biomarker for the detection of significant prostate cancer in individuals at risk for the disease.

Plasma GOAT enzyme levels show...

09/12/2018

Oncology